ARANA LOSES CEO DR JOHN CHIPLIN
November 8th 2008 05:30
Thursday November 6, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: GENETIC TECHNO UP 20%, NEUREN DOWN 15%
* FDA EXTENDS VENTRACOR TRIAL; OCTOBER REVENUE ‘A RECORD’
* ARANA LOSES CEO DR JOHN CHIPLIN TO AMERICA
* CORRECTION: AVEXA
* METABOLOMICS AUSTRALIA RESEARCH FACILITY OPENED
* SINGAPORE PATENT FOR BENITEC’S RNAI
* US PATENT NOTICE FOR VIRALYTICS EVATAK
* EUROPEAN PATENT FOR ROCKEBY’S THRUSH TEST
* ATCOR BACKS DIRECTOR OPTIONS; DIVIDES ON MICHAEL O’ROURKE
* MEDICAL DEVELOPMENTS BEGINS SHARE BUY-BACK
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
ARANA
Arana has announced the resignation of chief executive officer and managing director Dr John Chiplin.
In a media release to the ASX, Arana chairman Robin Beaumont said that in his three years at the company Dr Chiplin had led it “through a period of rapid change and significant progress, including the sale of Peptech’s Domantis shareholding, the successful merger last year of Peptech with Evogenix and the rationalization and focusing of the technology portfolio”.
“The board and John have now determined that this is an appropriate time to transition the CEO role and we will now focus on ensuring that his replacement will be the best available person to lead Arana in its next stage of development,” Mr Beaumont said.
Mr Beaumont told Biotech Daily that Dr Chiplin had been intending to return to the US for some time.
Dr Chiplin’s email at Arana was shut down immediately after the announcement was made.
Mr Beaumont said Arana would begin a search for a new chief executive officer, as well as appointing an acting CEO.
Arana climbed two cents or 2.58 percent to 79.5 cents.
SIZE=2]To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au [/SIZE]
| 10 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
